Source: Eur Respir Rev 2015; 24: 516-524
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Müller-Redetzky Holger, Lienau Jasmin, Suttorp Norbert, Witzenrath Martin. Therapeutic strategies in pneumonia: going beyond antibiotics. Eur Respir Rev 2015; 24: 516-524

Member's Comments

No comment yet.

Related content which might interest you: Update on therapeutic strategies in community-acquired pneumonia    Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021 Year: 2021 Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013 Could the initial use of antipseudomonal agents improve the prognosis for non-hospital acquired pneumonia? Source: Annual Congress 2013 –Pneumonia and sepsis Year: 2013 Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim? Source: Breathe, 17 (3) 210056; 10.1183/20734735.0056-2021 Year: 2021 Whether there are pharmacoeconomic and other advantages of using procalcitonin-guide antibacterial treatment in patients with severe community-acquired pneumonia in developing countries? Source: International Congress 2015 – Pneumonia: determinants of clinical outcomes and potential strategies to improve its management Year: 2015 Cost-effective antibiotic management of community acquired pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=198 Year: 2004 Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP) Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Rational use and stewardship of antibiotics in pediatric respiratory disease Source: ERS Courses: Paediatric respiratory infections Year: 2019 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Pneumococcal pneumonia: an old disease with radically-new approaches for antibiotic therapy Source: Annual Congress 2005 - Outcome in severe pneumonia Year: 2005 Management of community-acquired pneumonia: new evidence-based algorithms. Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections Year: 2021 Are antimicrobials still the future of respiratory infection therapy? Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections Year: 2021 Promising prophylactic means and methods for prevention of community-acquired pneumonia and respiratory infections among servicemen in Russia Source: Eur Respir J 2006; 28: Suppl. 50, 350s Year: 2006 Antibiotic prescribing in acute respiratory infections – are we following guidelines? Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Bacterial infections and indications for treatment with antibiotics in paediatric asthma? Source: Annual Congress 2010 - High-priority questions on airway infections in diseases seen in children and adults Year: 2010 Corticosteroids for community-acquired pneumonia: are we still there? Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Pneumococcal pneumonia in hospitalized patients. Therapeutic implications of resistances to penicillin and erythromycin Source: Eur Respir J 2003; 22: Suppl. 45, 543s Year: 2003